Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma

Therapeutic options for treating advanced melanoma have progressed rapidly in recent decades. Until 6 years ago, the regimen for treating advanced melanoma consisted mainly of cytotoxic agents such as dacarbazine and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimura, Taku, Muto, Yusuke, Asano, Yoshihide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779655/
https://www.ncbi.nlm.nih.gov/pubmed/36555362
http://dx.doi.org/10.3390/ijms232415720
_version_ 1784856662738206720
author Fujimura, Taku
Muto, Yusuke
Asano, Yoshihide
author_facet Fujimura, Taku
Muto, Yusuke
Asano, Yoshihide
author_sort Fujimura, Taku
collection PubMed
description Therapeutic options for treating advanced melanoma have progressed rapidly in recent decades. Until 6 years ago, the regimen for treating advanced melanoma consisted mainly of cytotoxic agents such as dacarbazine and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have been recognized as anchor drugs for treating advanced melanoma, with or without additional combination drugs such as ipilimumab, but the efficacies of these immunotherapies are not fully satisfactory. In this review, we describe the development of the currently available anti-PD1 Abs-based immunotherapies for advanced melanoma, focusing on their efficacy and immune-related adverse events (AEs), as well as clinical trials still ongoing for the future treatment of advanced melanoma.
format Online
Article
Text
id pubmed-9779655
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97796552022-12-23 Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma Fujimura, Taku Muto, Yusuke Asano, Yoshihide Int J Mol Sci Review Therapeutic options for treating advanced melanoma have progressed rapidly in recent decades. Until 6 years ago, the regimen for treating advanced melanoma consisted mainly of cytotoxic agents such as dacarbazine and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have been recognized as anchor drugs for treating advanced melanoma, with or without additional combination drugs such as ipilimumab, but the efficacies of these immunotherapies are not fully satisfactory. In this review, we describe the development of the currently available anti-PD1 Abs-based immunotherapies for advanced melanoma, focusing on their efficacy and immune-related adverse events (AEs), as well as clinical trials still ongoing for the future treatment of advanced melanoma. MDPI 2022-12-11 /pmc/articles/PMC9779655/ /pubmed/36555362 http://dx.doi.org/10.3390/ijms232415720 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Fujimura, Taku
Muto, Yusuke
Asano, Yoshihide
Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
title Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
title_full Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
title_fullStr Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
title_full_unstemmed Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
title_short Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
title_sort immunotherapy for melanoma: the significance of immune checkpoint inhibitors for the treatment of advanced melanoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779655/
https://www.ncbi.nlm.nih.gov/pubmed/36555362
http://dx.doi.org/10.3390/ijms232415720
work_keys_str_mv AT fujimurataku immunotherapyformelanomathesignificanceofimmunecheckpointinhibitorsforthetreatmentofadvancedmelanoma
AT mutoyusuke immunotherapyformelanomathesignificanceofimmunecheckpointinhibitorsforthetreatmentofadvancedmelanoma
AT asanoyoshihide immunotherapyformelanomathesignificanceofimmunecheckpointinhibitorsforthetreatmentofadvancedmelanoma

Ejemplares similares